NCT04871412RecruitingPhase 3
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care - The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial - Stage III
Source: ClinicalTrials.gov · Last updated 30 Jan 2026
Brief summary (registry, in English)
Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (\~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care. Too many clinical trials focus on single agent therapies, rather than broad multi-faceted individualized and integrative care interventions that are used in real world settings. The Thoracic POISE project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 12 Apr 2021
- Start date
- 4 Apr 2022
- Primary completion date
- 1 Dec 2028
- Lead sponsor
- Ottawa Hospital Research Institute
- Diseases
- Lung cancer, Gastric and esophageal cancer
- NCT number
- NCT04871412
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 20
- From 4 Apr 2022 to the primary completion date, 1 Dec 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently receiving care guided by an ND or who have previously seen an ND in the last 3 months
- Use of an investigational drug or participation in an investigational study within 30 days prior to starting the study
Other illness
- Any wedge resections of lung cancer
- History of cancer with active treatment in the last 3 years (not including superficial bladder cancer or non-melanoma skin cancer)
Other
- Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours
- Pregnant or breastfeeding women\*
- Any reason which, in the opinion of the Principal Investigator (or delegate), would prevent the subject from participating in the study
Who the study is looking for
- Adults eligible for complete resection of lung, gastric or esophageal cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Ottawa Hospital Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
| Michael Garron Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.